Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

Jasper Therapeutics’ stock has dropped by more than 50% after the company announced it was looking into the impact of a ...

P YC Therapeutics is set to begin Part B in its single ascending dose (SAD) study of the drug candidate, PYC-003, for ...

Cognito Therapeutics has reached its enrolment goal for the randomised, sham-controlled HOPE Study investigating the Spectris ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment ...

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

Rinri Therapeutics, a leading University of Sheffield spin-out company dedicated to transforming the treatment of ...

Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: With the 100th participant enrolled in the XanaMIA trial, the timeline ...

Australian researchers will soon deploy a psychedelic compound found in “magic mushrooms” to treat binge-eating in a ...